Valerio Therapeutics

ALVIO

Company Profile

  • Business description

    Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using two proprietary platforms: the PlatON platform and its DNA decoy mechanism of action, and the V-Body platform generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-ofconcept, a value-creating inflection point appealing to potential partners. Its pipline includes Metabolic Diseases, Immunology & Inflammatory, and Oncology.

  • Contact

    49, Boulevard du General
    Martial Valin
    Paris75015
    FRA

    T: +33 145587600

    https://www.valeriotx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    38

Stocks News & Analysis

stocks

Palantir earnings: Blockbuster growth amid high expectations

We raise our fair value estimate off the back of earnings.
stocks

ResMed earnings: Solid showing from ASX healthcare winner

Strong demand growth and improved profit margins lead to a strong result from the sleep apnea device firm.
stocks

Is this the $80 billion elephant Warren Buffett has been waiting for?

Morningstar’s Greg Warren says Berkshire may have little choice but to take a hard look at this huge potential acquisition.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,088.2059.400.66%
CAC 407,621.0410.97-0.14%
DAX 4023,846.0788.380.37%
Dow JONES (US)44,111.7461.90-0.14%
FTSE 1009,142.7314.430.16%
HKSE24,902.53169.080.68%
NASDAQ20,916.55137.03-0.65%
Nikkei 22540,529.1220.42-0.05%
NZX 50 Index12,905.1228.080.22%
S&P 5006,299.1930.75-0.49%
S&P/ASX 2008,823.5053.100.61%
SSE Composite Index3,617.6034.290.96%

Market Movers